dimethyl fumarate (tecfidera) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Dimethyl fumarate (DMF) is the methyl ester of fumaric acid and is named after the earth smoke plant. Dimethyl fumarate combined with three other fumaric acid esters (FAEs) is solely licensed in Germany as an oral therapy for psoriasis. Since 2013, it has been approved by the U.S. Food and Drug Administration (FDA) as a treatment option for adults with relapsing multiple sclerosis. In 2017, an oral formulation of dimethyl fumarate was approved for medical use in the European Union as a treatment for moderate-to-severe plaque psoriasis. Dimethyl fumarate is thought to have immunomodulatory properties without causing significant immunosuppression.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.9257 - $120.3093

Australia

$16.9395 - $16.9530
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1,2-bis(methoxycarbonyl)-trans-ethylene | azl-0211089 | bg00012 | bg-12 | boletic acid dimethyl ester | dimethyl (e) butenedioate | dimethyl fumar | dimethylfumarate | dimethyl fumarate | dimethyl trans-ethylenedicarboxylate | (e)-but-2-enedioic acid dimethyl ester | fp187 | fumaric acid, dimethyl ester | las41008 | lasw1835 | methyl fumarate | tecfidera | trans-1,2-ethylenedicarboxylic acid dimethyl ester | trans-butenedioic acid dimethyl ester

Organizations (63)

Research & Development (46)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (19)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (1)


 

Multiple Sclerosis

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Arthritis, Psoriatic (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Cerebral Hemorrhage (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2/Phase 3)

Glioblastoma (Phase 1)

Gliosarcoma (Phase 1)

Healthy Volunteers (Phase 3)

Hypertension, Pulmonary (Phase 1)

Inflammation (Phase 4)

Intracranial Aneurysm (Phase 4)

Ischemic Stroke (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Macular Degeneration (Phase 2)

Multiple Sclerosis ()

Multiple Sclerosis, Chronic Progressive (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 4)

Polymorphism, Genetic (Phase 2/Phase 3)

Psoriasis (Phase 4)

Renal Insufficiency, Chronic (Phase 2/Phase 3)

Scleroderma, Systemic (Phase 1)

Sleep Apnea, Obstructive (Phase 2)

Sleep Apnea Syndromes (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 69
  • # of Trial Organizations: 46

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue